A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson’s disease - Rascol, O; Ferreira, J; Nègre-Pages, L (Fundam Clin Pharmacol, 2012)
doi: 10.1111/j.1472-8206.2011.00951.x.